Risk-Stratified Approach to Breast Cancer Screening in Canada: Women's Knowledge of the Legislative Context and Concerns about Discrimination from Genetic and Other Predictive Health Data.
breast cancer
genetic discrimination
population survey
risk-stratified screening
women’s perspectives
Journal
Journal of personalized medicine
ISSN: 2075-4426
Titre abrégé: J Pers Med
Pays: Switzerland
ID NLM: 101602269
Informations de publication
Date de publication:
27 Jul 2021
27 Jul 2021
Historique:
received:
04
07
2021
revised:
17
07
2021
accepted:
26
07
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
The success of risk-stratified approaches in improving population-based breast cancer screening programs depends in no small part on women's buy-in. Fear of genetic discrimination (GD) could be a potential barrier to genetic testing uptake as part of risk assessment. Thus, the objective of this study was twofold. First, to evaluate Canadian women's knowledge of the legislative context governing GD. Second, to assess their concerns about the possible use of breast cancer risk levels by insurance companies or employers. We use a cross-sectional survey of 4293 (age: 30-69) women, conducted in four Canadian provinces (Alberta, British Colombia, Ontario and Québec). Canadian women's knowledge of the regulatory framework for GD is relatively limited, with some gaps and misconceptions noted. About a third (34.7%) of the participants had a lot of concerns about the use of their health information by employers or insurers; another third had some concerns (31.9%), while 20% had no concerns. There is a need to further educate and inform the Canadian public about GD and the legal protections that exist to prevent it. Enhanced knowledge could facilitate the implementation and uptake of risk prediction informed by genetic factors, such as the risk-stratified approach to breast cancer screening that includes risk levels.
Identifiants
pubmed: 34442372
pii: jpm11080726
doi: 10.3390/jpm11080726
pmc: PMC8398750
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Genome Canada
ID : 13529
Références
Clin Genet. 2013 Sep;84(3):251-7
pubmed: 23167775
Eur J Hum Genet. 2012 Oct;20(10):1018-23
pubmed: 22453290
Ann Surg Oncol. 2021 Aug;28(8):4306-4317
pubmed: 33398646
Fam Cancer. 2012 Dec;11(4):637-44
pubmed: 22890887
Am J Hum Genet. 2019 Jan 3;104(1):21-34
pubmed: 30554720
Genome Med. 2021 Jan 28;13(1):14
pubmed: 33509269
Annu Rev Genomics Hum Genet. 2020 Aug 31;21:491-507
pubmed: 31961723
Nature. 2003 Jan 23;421(6921):313
pubmed: 12540874
Breast Cancer Res Treat. 2019 Jul;176(1):141-148
pubmed: 30941651
Nat Rev Genet. 2002 Jul;3(7):496
pubmed: 12109463
J Clin Oncol. 2017 Dec 1;35(34):3800-3806
pubmed: 28820644
J Hum Genet. 2016 Apr;61(4):275-82
pubmed: 26740237
J Genet Couns. 2020 Dec;29(6):928-935
pubmed: 31850620
J Pers Med. 2021 Feb 02;11(2):
pubmed: 33540785
Nat Genet. 2020 May;52(5):466-468
pubmed: 32203466
J Genet Couns. 2015 Jun;24(3):512-21
pubmed: 25242499
Genet Test Mol Biomarkers. 2019 Feb;23(2):75-83
pubmed: 30676117
Nat Rev Clin Oncol. 2020 Nov;17(11):687-705
pubmed: 32555420
JCO Oncol Pract. 2020 Jan;16(1):e37-e55
pubmed: 31613719
J Genet Couns. 2015 Dec;24(6):1022-36
pubmed: 25925606
J Natl Cancer Inst. 2017 Jan 27;109(5):
pubmed: 28130475
Front Genet. 2017 Sep 21;8:128
pubmed: 28983318
J Pers Med. 2021 Jun 04;11(6):
pubmed: 34199804